Nothing has changed from what they said in August, why would it.
A small amount of product has been produced recently to facilitate FDA required clinical studies and distribution trials during FY24. And from the FY 24 outlook - The Company expects growth in other nutritional products and modest growth in ANZ and USA liquid milk. USA IMF sales are expected to be immaterial.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)